Gabriel M.I. Mecklenburg, Executive Chairman and Co-Founder of Hinge Health, Inc. (NASDAQ:HNGE), sold 200,000 shares of the company's Class A Common Stock for a total of $24,482,096 on November 11, 2026, according to a regulatory filing. The shares were sold at weighted average prices ranging from $121.7581 to $125.5041 per share, a range that sits close to the stock's 52-week high of $126.40. The company has delivered a 182% return over the past year, though an analysis provided by InvestingPro suggests the stock is currently overvalued relative to its Fair Value.
The sales were executed pursuant to a Rule 10b5-1 trading plan, which Mecklenburg adopted on June 12, 2026. Such plans allow company insiders to set up predetermined schedules for buying or selling shares, providing a defense against allegations of trading on material nonpublic information.
On the same day, Mecklenburg also converted 200,000 shares of Class B Common Stock into Class A Common Stock at no cost. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election or automatically upon certain transfers or events.
Following these transactions, Mecklenburg directly holds no Class A Common Stock. He continues to hold 1,444,004 shares of Class B Common Stock directly. In addition, he indirectly holds 383,592 shares of Class B Common Stock through a Family Trust and 692,710 shares of Class B Common Stock through a Grantor Retained Annuity Trust (GRAT).
In other recent news, Hinge Health reported strong financial performance in the third quarter, with revenue reaching $235 million, marking a 52% increase year-over-year. This figure surpassed both Canaccord's estimate of $224 million and the company's guidance of $223 million to $225 million. The company's non-GAAP operating income was $77.2 million, with a margin of 33%, exceeding Canaccord's expectations of $62.7 million and a 28% margin.
Stifel, Canaccord, Needham, and Wells Fargo all raised their price targets for Hinge Health, reflecting confidence in the company's performance. Stifel increased its target to $135, while Canaccord set theirs at $134. Needham also raised its target to $135, citing strong client growth as a significant factor. Wells Fargo adjusted its price target to $132, noting the company's yield strength and exceeding consensus estimates in revenue and adjusted EBIT. These developments highlight the positive sentiment among analysts regarding Hinge Health's recent achievements.